Glaxo Wellcome Relenza
Executive Summary
"Dear Healthcare Professional" letter sent July 10 to highlight addition of bolded warning to zanamivir labeling. The warning addresses events of bronchospasm and decline in lung function reported in some patients, and advises against Relenza administration to patients with underlying airway disease such as asthma or chronic obstructive pulmonary disease (1"The Pink Sheet" Jan. 31, p. 20). A new patient information leaflet has been developed, and a second "Dear Healthcare Professional" letter will be mailed at the beginning of the flu season in the fall